Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
A new tool from the European Network For Health Technology Assessment to evaluate the quality of registries is now being piloted.
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
The Labour Party says it would overhaul the system for pricing medicines in the UK by de-linking innovation and price incentives if it gets into office at the next general election.
The UK’s main opposition party is proposing to create a publicly owned generics company, should it win the next general election.
The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.